Omega Diagnostics Group PLC DHSC contract update (2678V)
10 Diciembre 2021 - 3:29AM
UK Regulatory
TIDMODX
RNS Number : 2678V
Omega Diagnostics Group PLC
10 December 2021
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
DHSC contract update
Omega (AIM: ODX), the specialist medical diagnostics company
focused on industry-leading Global Health (CD4 and COVID-19) and
Health and Nutrition products, provides an update in relation to
the Company's contract with the Department of Health and Social
Care ("DHSC") to provide manufacturing capacity for COVID-19
lateral flow antigen tests. As previously disclosed, the DHSC was
unable to move into Phase 2 of the contract, which would have seen
Omega progress to manufacturing tests using Government-furnished
equipment.
Omega has received confirmation from the DHSC that they
acknowledge that the contract expired on 1 October 2021 and a
request that Omega submit a proposal for the repayment of the
pre-production payment of GBP2.5m (net of VAT).
The Board of Omega, having taken initial legal advice, do not
believe that the Company is required to repay the pre-production
payment and will respond in writing as requested. The Board will
continue to take further legal advice on this matter and hopes to
reach a resolution swiftly.
Colin King, CEO, Omega Diagnostics, said: "It is clearly
disappointing to receive this request for repayment given the
efforts we have gone to ensure manufacturing capacity for COVID-19
lateral flow test was available for the DHSC and that we did not
progress to Phase 2 of the contract due to the lack of confirmation
from the DHSC regarding which test they require us to
manufacture.
"Acting in good faith we used these pre-production payments,
along with our own funds, to upgrade our manufacturing facilities
to be able to integrate the Government-furnished equipment and
bringing on the additional staff required to be able to supply the
DHSC using our UK-based volume manufacturing services. We therefore
are confident that, having sought legal advice, we will not be
required to make this repayment."
Contacts:
Omega Diagnostics Group PLC www.omegadx.com
Colin King, Chief Executive Officer via Walbrook PR
Chris Lea, Chief Financial Officer
finnCap Ltd Tel: 020 7220 0500
Geoff Nash/Edward Whiley (Corporate
Finance)
Alice Lane/ Charlotte Sutcliffe
(ECM)
Walbrook PR Limited Tel: 020 7933 8780 or omega@walbrookpr.com
Paul McManus Mob: 07980 541 893
Lianne Applegarth Mob: 07584 391 303
Sam Allen Mob: 07502 558 258
About Omega Diagnostics Group PLC
Omega manufactures and distributes high quality in-vitro
diagnostic products for use in hospitals, clinics, laboratories and
healthcare practitioners in over 75 countries and specialise in the
areas of health and nutrition and global health.
www.omegadx.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTURUKRANUUARA
(END) Dow Jones Newswires
December 10, 2021 04:29 ET (09:29 GMT)
Omega Diagnostics (LSE:ODX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Omega Diagnostics (LSE:ODX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024